Application of Response Evaluation Criteria of Traditional Chinese Medicine for Solid Tumor in advanced non-small cell lung cancer

Nuan-zhu Xue; Ruo-ming Fang; Li-zhu Lin

doi:10.1007/s11655-014-2022-0

Your Location：

Home >

Browse articles >

Application of Response Evaluation Criteria of Traditional Chinese Medicine for Solid Tumor in advanced non-small cell lung cancer

Updated：2021-08-27

- Application of Response Evaluation Criteria of Traditional Chinese Medicine for Solid Tumor in advanced non-small cell lung cancer
- Chinese Journal of Integrative Medicine Vol. 20, Issue 12, Pages: 910-916(2014)
- Affiliations：
  
  1. Guangzhou University of Chinese Medicine,Guangzhou,China
  2. Department of Oncology, First Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-014-2022-0
  CLC：
- Published：2014，
  
  Published Online：27 November 2014，
Scan for full text
Xue, Nz., Fang, Rm. & Lin, Lz. Application of Response Evaluation Criteria of Traditional Chinese Medicine for Solid Tumor in advanced non-small cell lung cancer., Chin. J. Integr. Med. 20, 910–916 (2014). https://doi.org/10.1007/s11655-014-2022-0

Nuan-zhu Xue, Ruo-ming Fang, Li-zhu Lin. Application of Response Evaluation Criteria of Traditional Chinese Medicine for Solid Tumor in advanced non-small cell lung cancer. [J]. Chinese Journal of Integrative Medicine 20(12):910-916(2014)
Xue, Nz., Fang, Rm. & Lin, Lz. Application of Response Evaluation Criteria of Traditional Chinese Medicine for Solid Tumor in advanced non-small cell lung cancer., Chin. J. Integr. Med. 20, 910–916 (2014). https://doi.org/10.1007/s11655-014-2022-0 DOI：

Nuan-zhu Xue, Ruo-ming Fang, Li-zhu Lin. Application of Response Evaluation Criteria of Traditional Chinese Medicine for Solid Tumor in advanced non-small cell lung cancer. [J]. Chinese Journal of Integrative Medicine 20(12):910-916(2014) DOI： 10.1007/s11655-014-2022-0.

摘要

To evaluate the objectivity and comprehensiveness of Response Evaluation Criteria of Traditional Chinese Medicine for Solid Tumor (Draft

REC-TCM-ST) in application of Chinese medicine therapeutic effect in patients with advanced non-small cell lung cancer (NSCLC). A retrospective clinical research was used in 104 NSCLC patients in stages of III–IV

53 cases were in Chinese medicine (CM) group and 51 cases were in Western medicine (WM) group. The therapeutic effect of the two groups was evaluated with both REC-TCM-ST and Response Evaluation Criteria in Solid Tumor (RECIST). Kaplan-Meier method was used to analyze the survival time. Kappa test method was used to test the consistency of the two kinds of evaluation results. According to REC-TCM-ST

the effective rate on relieving tumor mass in the CM group was significantly lower than that in the WM group (P<0.05)

but there was no significant difference in tumor-mass stable rate (P>0.05); the symptom of weakness in the CM group was improved significantly

indicating better therapeutic effect than that in the WM group (P<0.01). Karnofsky score in the CM group was significantly better than that in the WM group (P<0.01). In terms of survival conditions

the median survival time and the survival rate of 6 months

1 year and 2 years of the CM group were higher than the WM group. The total effective rate was 9.62%

and the total stable rate was 72.12% for 104 cases according to RECIST; while the total effective rate was 34.62%

and the total stable rate was 84.62% according to REC-TCM-ST

thus there were significant differences between the results of the two criteria (P<0.01)

and there was also some consistency between them

but not satisfactory. REC-TCM-ST was used to evaluate the therapeutic effect of CM in the treatment of advanced NSCLC

which shows that its evaluation results can better reflect the advantages and disadvantages of CM

and the effectiveness of CM is more objective and comprehensive than RECIST

so REC-TCM-ST is worthy of further improvement and clinical expansion.

Abstract

To evaluate the objectivity and comprehensiveness of Response Evaluation Criteria of Traditional Chinese Medicine for Solid Tumor (Draft

the effective rate on relieving tumor mass in the CM group was significantly lower than that in the WM group (P<0.05)

but there was no significant difference in tumor-mass stable rate (P>0.05); the symptom of weakness in the CM group was improved significantly

indicating better therapeutic effect than that in the WM group (P<0.01). Karnofsky score in the CM group was significantly better than that in the WM group (P<0.01). In terms of survival conditions

the median survival time and the survival rate of 6 months

1 year and 2 years of the CM group were higher than the WM group. The total effective rate was 9.62%

and the total stable rate was 72.12% for 104 cases according to RECIST; while the total effective rate was 34.62%

and the total stable rate was 84.62% according to REC-TCM-ST

thus there were significant differences between the results of the two criteria (P<0.01)

and there was also some consistency between them

but not satisfactory. REC-TCM-ST was used to evaluate the therapeutic effect of CM in the treatment of advanced NSCLC

which shows that its evaluation results can better reflect the advantages and disadvantages of CM

and the effectiveness of CM is more objective and comprehensive than RECIST

so REC-TCM-ST is worthy of further improvement and clinical expansion.

关键词

therapeutic effect evaluationnon-small cell lung cancerChinese medicine therapymalignant tumor

Keywords

therapeutic effect evaluationnon-small cell lung cancerChinese medicine therapymalignant tumor

references

Yang XZ. Therapeutic effect criterion for integrative treatment of traditional Chinese medicine and western medicine in cancer. J Tradit Chin Med (Chin) 2000;41:688–689.

Lin LZ, Lan SQ, Zhou DH. Trial on the therapeutic effect criterion of traditional Chinese medicine treatment for malignant tumors (solid). New J Tradit Chin Med (Chin) 2001;33:5–6.

Zhang PT. Clinical therapeutic effect criterion of traditional Chinese medicine on cancer. China Cancer (Chin) 1999;8:452–454.

Lin LZ, Lan SQ. Application of the assessment on life quality in the field of traditional Chinese medicine treatment on malignant tumors. J Guangzhou Univ Tradit Chin Med (Chin) 1999;16:158–160.

Lin LZ. Application of life quality in comprehensive therapeutic effect evaluation of traditional Chinese medicine oncology. China Cancer (Chin) 2001;10:80–82.

Zhou DH. Clinical traditional Chinese medicine oncology. Beijing: People’s Health Publishing House; 2003:617,620–622.

Medical Administration of the People’s Republic of China. Treatment specifications for common malignant tumor. Beijing: Chinese Peking Union Medical College Press; 1999:773–781.

Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710.

Zhang JJ, Meng Q, Chang W, Wan CH. The research progress and status of therapeutic evaluation for tumortreatment. Chin J Cancer (Chin) 2010;29:250–254.

Qiu M, Ying J, Liu L, Cheng J, Zhang Q, Liu Y. Research of therapeutic evaluation criteria of traditional Chinese medicine for tumor. Shanghai J Tradit Chin Med (Chin) 2012;46:7–10.

Tian JH, Zhu FP, Liu LS, Li HG, Xu L. “People-centered” therapeutic efficacy assessment criteria for Chinese medicine on solid tumor. Shanghai J Tradit Chin Med (Chin) 2012;46:3–6.

Lu DY, Ye XW. Application of QOL evaluation for TCM anticancer. J Anhui Tradit Chin Med (Chin) 2011;30(6):70–72.

FDA. Guidance for industry-patient-reported outcome measures: use in medical product development to support labeling claims, draft guidance. Health Qual Life Outcomes 2006;4:79.

Rock EP, Scott JA, Kennedy DL, Sridhara R, Pazdur R, Burke LB. Challenges to use of health-re-lated quality of life for Food and Drug Administration approval of anti-cancer products. J Natl Cancer Inst Monogr 2007;37:27–30.

FULL TEXT LINK

More>

Views

677

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Clinical study on long-term overall survival of advanced non-small-cell lung cancer patients treated with Chinese medicine and western medicine

Effect of Sangu Decoction (三骨汤) on metastatic bone destruction in rats with mammary cancer

Effect of Feitai Capsule (肺泰胶囊) on quality of life and progression-free survival of patients with unresectable non-small cell lung cancer

Establishing Chinese medicine characteristic tumor response evaluation system is the key to promote internationalization of Chinese medicine oncology

Clinical benefits as endpoints in advanced non-small cell lung cancer treated with integrative medicine

Related Author

No data

Related Institution

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Integrated Traditional Chinese and Western Medicine, Peking University Cancer Hospital & Institute

Beijing University of Chinese Medicine

Department of Chinese Medicine on Tumor, China-Japan Friendship Hospital

Fujian Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine

Department of Oncology, Fuzhou General Hospital, Nanjing Military Command

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰